Loading
Triple Negative Breast Cancer (TNBC) / SHR- A1811 / SHR- A1811+ eve · Phase 3 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 3 randomized controlled trial comparing trastuzumab rezetecan with or without everolimus in first-to-third-line locally advanced or metastatic LAR subtype triple-negative breast cancer. No results have been posted to the registry as of this record; the study has not yet begun recruitment.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Breast Cancer, Triple Negative Breast Cancer (TNBC); Female; age from 18 Years; to 70 Years. Intervention: Arm-A. Compared with: Arm-B — Active Comparator. n = 180.
This is a planned Phase 3 randomized controlled trial comparing trastuzumab rezetecan with or without everolimus in first-to-third-line locally advanced or metastatic LAR subtype triple-negative breast cancer. No results have been posted to the registry as of this record; the study has not yet begun recruitment.
No baseline characteristics, efficacy data, safety data, or outcome results are available in this record.
The source did not state who this applies to in practice.
This is a clinical trial registry record for a planned Phase 3 study with no results posted; recruitment has not yet begun.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07760844). This is a study registration, not published results. Lead sponsor: Fudan University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 180 participants (ESTIMATED). Conditions: Breast Cancer, Triple Negative Breast Cancer (TNBC). Interventions: DRUG: SHR- A1811+ eve; DRUG: SHR- A1811. Primary outcome measures: Progression Free Survival(PFS) , 24 months. Brief summary: This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the LAR subtype. A total of 180 patients are planned to be enrolled.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.